Literature DB >> 8252586

A proischaemic action of nisoldipine: relationship to a decrease in perfusion pressure and comparison to dipyridamole.

D Baumgart1, T Ehring, G Heusch.   

Abstract

OBJECTIVE: The calcium antagonist nisoldipine has recently been reported to induce rather than to attenuate ischaemia in some patients with stable angina. The aim of the study was to investigate the mechanisms underlying this proischaemic effect.
METHODS: In 20 anaesthetised dogs systemic haemodynamic variables, regional myocardial blood flow (coloured microspheres), and systolic wall thickening (sonomicrometry) were measured during control conditions and following severe stenosis on the left circumflex coronary artery, before and after intravenous administration of equihypotensive doses of either nisoldipine (group I, n = 10) or dipyridamole (group II, n = 10). Finally, measurements were performed while the drug induced decreases in mean aortic pressure--18 (SD 6) mmHg in group I and 14(6) mm Hg in group II--were reversed by inflation of an intra-aortic balloon.
RESULTS: The stenosis decreased posterior wall thickening to 50% of control, and posterior subendocardial blood flow from 1.48(0.27) to 0.61(0.19) ml.min-1.g-1 in group I and from 1.49(0.23) to 0.62(0.18) ml.min-1.g-1 in group II. Subendocardial blood flow was further decreased after administration of either nisoldipine [0.37(0.20) ml.min-1.g-1, p < 0.05 v stenosis] or dipyridamole [0.22(0.11) ml.min-1.g-1, p < 0.05 v stenosis]. Regional myocardial blood flow in the anterior region was increased. The drug induced reduction of subendocardial blood flow decreased posterior wall thickening further from 9.3(2.1) to 6.2(3.9)% (p < 0.05 v stenosis, group I) and from 9.1(1.7) to 4.3(2.4)% (p < 0.05 v stenosis, group II). When the drug induced decrease in aortic pressure was reversed, subendocardial blood flow again increased in group I [0.63(0.19) ml.min-1.g-1, p < 0.05 v stenosis and nisoldipine] whereas in group II it remained decreased [0.40(0.29) ml.min-1.g-1, NS v stenosis and dipyridamole]. There was restoration of posterior wall thickening in group I [10.4(3.8)%, p < 0.05 v stenosis and nisoldipine], but not in group II [5.2(3.5)%, NS v stenosis and dipyridamole].
CONCLUSIONS: Nisoldipine and dipyridamole decrease subendocardial blood flow and contractile function distal to a severe stenosis when aortic pressure is decreased. No aggravation of ischaemia by nisoldipine is seen when hypotension is prevented. In contrast, dipyridamole in the absence of hypotension still induces a redistribution of flow at the expense of the ischaemic region.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8252586     DOI: 10.1093/cvr/27.7.1254

Source DB:  PubMed          Journal:  Cardiovasc Res        ISSN: 0008-6363            Impact factor:   10.787


  8 in total

Review 1.  Ischemia-selectivity: a new concept of cardioprotection by calcium antagonists.

Authors:  G Heusch
Journal:  Basic Res Cardiol       Date:  1994 Jan-Feb       Impact factor: 17.165

Review 2.  Ivabradine in Patients with Stable Coronary Artery Disease: A Rationale for Use in Addition to and Beyond Percutaneous Coronary Intervention.

Authors:  Cosmo Godino; Antonio Colombo; Alberto Margonato
Journal:  Clin Drug Investig       Date:  2017-02       Impact factor: 2.859

Review 3.  Calcium antagonists in myocardial ischemia/reperfusion--update 2012.

Authors:  Petra Kleinbongard; Theodor Baars; Gerd Heusch
Journal:  Wien Med Wochenschr       Date:  2012-06-14

4.  Myocardial ischemia: lack of coronary blood flow, myocardial oxygen supply-demand imbalance, or what?

Authors:  Gerd Heusch
Journal:  Am J Physiol Heart Circ Physiol       Date:  2019-04-19       Impact factor: 4.733

5.  The safety and use of short-acting nifedipine in hospitalized hypertensive children.

Authors:  Verna Yiu; Elaine Orrbine; Rhonda J Rosychuk; Peter MacLaine; Paul Goodyer; Colette Girardin; Manjula Gowrishankar; Malcolm Ogborn; Julian Midgley; Guido Filler; Frances Harley
Journal:  Pediatr Nephrol       Date:  2004-03-31       Impact factor: 3.714

Review 6.  Heart rate in the pathophysiology of coronary blood flow and myocardial ischaemia: benefit from selective bradycardic agents.

Authors:  G Heusch
Journal:  Br J Pharmacol       Date:  2008-01-28       Impact factor: 8.739

Review 7.  A pathophysiological compass to personalize antianginal drug treatment.

Authors:  Edoardo Bertero; Gerd Heusch; Thomas Münzel; Christoph Maack
Journal:  Nat Rev Cardiol       Date:  2021-07-07       Impact factor: 32.419

Review 8.  Targeting myocardial ischaemic injury in the absence of reperfusion.

Authors:  M V Basalay; D M Yellon; S M Davidson
Journal:  Basic Res Cardiol       Date:  2020-10-14       Impact factor: 17.165

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.